Jejurikar, who joined P&G as an assistant brand manager in 1989, will replace Jon Moeller as part of a top leadership transition.

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Relief over a US-EU trade deal today benefited the FTSE 100 index in a session when leading European benchmarks rose by as ...

Novartis moves to block cancer drug generic in US ...

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 ...

Ninety percent of parents, expectant parents said they'd want to know early about SMA, and 80% said not screening newborns ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association's Cardiovascular-Kidney-Metabolic ...

By Adam Jourdan LONDON (Reuters) -European companies were on edge on Monday as corporate leaders tried to unpick the real impact of a hard-won U.S. trade deal and lamented a sharp jump in tariffs ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

July 28, 2025 - DALLAS People in 15 regions across the U.S. will soon benefit from the American Heart Association's ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...